DB:3T2

Stock Analysis Report

Executive Summary

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally.


Snowflake Analysis

Limited growth with weak fundamentals.


Similar Companies

Share Price & News

How has T2 Biosystems's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 3T2's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

49.8%

3T2

11.2%

DE Biotechs

7.3%

DE Market


1 Year Return

-73.6%

3T2

-5.1%

DE Biotechs

-17.7%

DE Market

Return vs Industry: 3T2 underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: 3T2 underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

3T2IndustryMarket
7 Day49.8%11.2%7.3%
30 Day-21.0%-5.3%-17.9%
90 Day-36.1%-21.9%-25.8%
1 Year-73.6%-73.6%-4.9%-5.1%-15.1%-17.7%
3 Year-87.2%-87.2%17.7%16.5%-18.7%-25.6%
5 Year-96.0%-96.0%-5.1%-7.5%-17.7%-29.0%

Price Volatility Vs. Market

How volatile is T2 Biosystems's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is T2 Biosystems undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether T2 Biosystems is trading at an attractive price based on the cash flow it is expected to produce in the future. But as T2 Biosystems has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is T2 Biosystems forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

9.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3T2 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 3T2 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 3T2 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 3T2's revenue (41.6% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: 3T2's revenue (41.6% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 3T2's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has T2 Biosystems performed over the past 5 years?

-7.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 3T2 is currently unprofitable.

Growing Profit Margin: 3T2 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 3T2 is unprofitable, and losses have increased over the past 5 years at a rate of -7.8% per year.

Accelerating Growth: Unable to compare 3T2's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 3T2 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: 3T2's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is T2 Biosystems's financial position?


Financial Position Analysis

Short Term Liabilities: 3T2 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 3T2 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: 3T2 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 3T2's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: 3T2 has a high level of physical assets or inventory.

Debt Coverage by Assets: 3T2 has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 3T2 has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: 3T2 has less than a year of cash runway if free cash flow continues to reduce at historical rates of -8.6% each year


Next Steps

Dividend

What is T2 Biosystems's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 3T2's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 3T2's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 3T2's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 3T2's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 3T2's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

John Sperzel (55yo)

0.17

Tenure

Mr. John J. Sperzel, III, B.Sc., serves as President, Chief Executive Officer and Director of T2 Biosystems, Inc. since January 8, 2020. Mr. Sperzel served as the Chief Executive Officer and President of C ...


Leadership Team

NamePositionTenureCompensationOwnership
Michael Cima
Co-Founder & Director14.17yrsUS$147.28k0.21% $124.2k
John Sprague
CFO & Senior VP2.17yrsUS$1.50m0.022% $12.9k
Thomas Lowery
Chief Scientific Officer6.5yrsUS$1.36m0.068% $40.2k
John Sperzel
President0.17yrno datano data
Tyler Jacks
Co-Founder14.17yrsno datano data
Lee Josephson
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Alec Barclay
Senior Vice President of Operations2yrsno data0.046% $27.0k
Michael Gibbs
VP & General Counsel4.17yrsno data0.060% $35.4k
Kelley Morgan
Vice President of Human Resources6yrsno datano data
Anthony Pare
Chief Commercial Officer0.17yrno data0.0045% $2.7k

4.2yrs

Average Tenure

55yo

Average Age

Experienced Management: 3T2's management team is considered experienced (4.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Michael Cima
Co-Founder & Director14.17yrsUS$147.28k0.21% $124.2k
John Sperzel
President0.17yrno datano data
Lee Josephson
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Alexander Klibanov
Member of Scientific Advisory Boardno datano datano data
Stanley Lapidus
Independent Director11.58yrsUS$176.28k0.053% $30.9k
John McDonough
Non-Executive Chairman0.67yrUS$4.02m0.49% $285.0k
David Elsbree
Independent Director5.67yrsUS$152.79k0.10% $58.9k
Harold Kisner
Member of Scientific Advisory Boardno datano datano data
T. Boles
Member of Scientific Advisory Boardno datano datano data
Peter Pappas
Member of Clinical Advisory Board8.83yrsno datano data

7.3yrs

Average Tenure

64yo

Average Age

Experienced Board: 3T2's board of directors are considered experienced (7.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.2%.


Top Shareholders

Company Information

T2 Biosystems, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: T2 Biosystems, Inc.
  • Ticker: 3T2
  • Exchange: DB
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$65.086m
  • Listing Market Cap: US$58.701m
  • Shares outstanding: 100.75m
  • Website: https://www.t2biosystems.com

Number of Employees


Location

  • T2 Biosystems, Inc.
  • 101 Hartwell Avenue
  • Lexington
  • Massachusetts
  • 2421
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TTOONasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDAug 2014
3T2DB (Deutsche Boerse AG)YesCommon StockDEEURAug 2014

Biography

T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 23:41
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.